GlobeNewswire BiotechnologyDoubao · 实盘不做把握 8/10不做原因:无增量信息🔁 +1 同一事件
北京时间·🕒 发布 05:00:00·⟳ 抓取 05:00:53·⚡ 决策 10-19 05:02:09 +1m16s·8.9 天前
Disc Medicine预告将于10月19日盘前电话会披露bitopertin治疗EPP的APOLLO III期顶线结果，数据尚未公布
这是一条临床读出前的日程预告，不含任何阳性/阴性结果；III期顶线是典型二元事件，在数据公布前做多或做空均无事实依据与edge，且此刻美股闭市无法成交，应等10月19日08:00 ET顶线数据后再研判。
📄 原文GlobeNewswire Biotechnology↗ 原文
WATERTOWN, Mass., Oct. 18, 2026 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutic…
不做 Disc Medicine（IRON.US）
仅为III期顶线读出前的日程预告，无任何疗效/安全性数据，二元事件方向不可判、无edge；且当前美股周日闭市无法成交。等2026-10-19 08:00 ET顶线公布后，依据主要终点、p值/效应量与安全性再决定多空，数据前不裸赌跳空。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
结论摘要
Disc Medicine仅预告周一盘前披露APOLLO III期顶线结果，没有任何数据，无法判断成功或失败；在二元临床读出前裸赌方向不具正期望，故回避，待数据落地后按终点达成、效应量与安全性重新决策。
🔎 新鲜度:最早出现 2026-10-18 · 扩散 low · price-in 风险 medium ↗
关键理由
- 当前稿件无任何临床数据，事件状态仍停留在「III期待读出」，不构成方向性利多或利空
- 真正的价格驱动在约15小时后的盘前顶线，届时才有可交易的预期差
主要风险
- III期顶线为二元事件，盘前可能大幅跳空，数据前持仓无法控制隔夜缺口风险
- 即使标题阳性，仍需核查效应量、p值、安全性与完整数据，标题利好可能高开低走
反向证据
- 做多前查反向 · 来源 web · 影响 none
本稿及已查证据中无任何结果方向、分析师上调或合作/授权新信息，缺乏做多事实依据
检索:Disc Medicine bitopertin APOLLO phase 3 EPP results data leaked positive negative 原文 ↗
先例如何影响了这次决策
对本次决策的影响:支持在数据公布前回避，不在本信号下给任何方向性ENTER
方向:当前为读出前预告、无数据，不宜用历史III期读出先例在数据前定方向；先例只应在周一顶线公布后用于校准阳性/阴性各自的幅度。
涨幅量级:数据未出，无法选取对齐先例校准tp/sl
形态:小盘临床期生技III期顶线普遍盘前大幅跳空、双向波动剧烈，强化数据前不持仓
工具执行结果 · 成功 2 · 降级 0 · 失败 0 · 取消 0
- search_processed_events 成功 stock_tools HTTP · 15 ms
{"result": "search_processed_events:agent query=`disc medicine bitopertin apollo phase 3 topline results epp webcast | iron bitopertin apollo phase 3 erythropoietic protoporphyria data october 2026`；结构化索引覆盖完整 72 小时；旧记录兼容扫描近 0.0/72 小时、0 条本臂决策(完整)，返回 0 条候选。未命中只表示这些 agent query 表达式没有召回候选，不能据此证明消息首发或不是重 - fetch_decision_experience 成功 stock_tools_inprocess · 3 ms
{
原文全文
展开原文 · 2,428 字
WATERTOWN, Mass., Oct. 18, 2026 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, today announced it will host a corporate webcast to discuss topline results from the APOLLO Phase 3 trial of bitopertin in EPP. The webcast will be held on Monday, October 19, 2026 at 8:00 a.m. ET.
Webcast Information
Please register for the event on the Events and Presentations page of Disc’s website at
https://ir.discmedicine.com
.
A replay of the webcast will be made available on the website following the call.
About Bitopertin
Bitopertin is an investigational, clinical-stage, orally administered inhibitor of glycine transporter 1 (GlyT1) that is designed to modulate heme biosynthesis. GlyT1 is a membrane transporter expressed on developing red blood cells and is required to supply sufficient glycine for heme biosynthesis and support erythropoiesis. Disc is developing bitopertin as a potential treatment for a range of hematologic diseases including erythropoietic porphyrias, where it has potential to be the first disease-modifying therapy. Bitopertin has been studied in multiple clinical trials in patients with EPP, including the Phase 2 open-label BEACON trial, the Phase 2 double-blind, placebo-controlled AURORA trial, an open-label extension HELIOS trial, and the Phase 3 double-blind, placebo-controlled APOLLO trial.
Bitopertin is an investigational agent and is not approved for use as a therapy in any jurisdiction worldwide. Disc obtained global rights to bitopertin under a license agreement from Roche in May 2021.
About Disc Medicine
Disc Medicine (NASDAQ:IRON) is a clinical-stage biopharmaceutical company committed to discovering, developing, and commercializing novel treatments for patients who suffer from serious hematologic diseases. We are building a portfolio of innovative, potentially first-in-class therapeutic candidates that aim to address a wide spectrum of hematologic diseases by targeting fundamental biological pathways of red blood cell biology, specifically heme biosynthesis and iron homeostasis. For more information, please visit
www.discmedicine.com
.
Media Contact
Peg Rusconi
Deerfield Group
peg.rusconi@deerfieldgroup.com
Investor Relations Contact
Kevin Lui
Precision AQ
kevin.lui@precisionaq.com
Webcast Information
Please register for the event on the Events and Presentations page of Disc’s website at
https://ir.discmedicine.com
.
A replay of the webcast will be made available on the website following the call.
About Bitopertin
Bitopertin is an investigational, clinical-stage, orally administered inhibitor of glycine transporter 1 (GlyT1) that is designed to modulate heme biosynthesis. GlyT1 is a membrane transporter expressed on developing red blood cells and is required to supply sufficient glycine for heme biosynthesis and support erythropoiesis. Disc is developing bitopertin as a potential treatment for a range of hematologic diseases including erythropoietic porphyrias, where it has potential to be the first disease-modifying therapy. Bitopertin has been studied in multiple clinical trials in patients with EPP, including the Phase 2 open-label BEACON trial, the Phase 2 double-blind, placebo-controlled AURORA trial, an open-label extension HELIOS trial, and the Phase 3 double-blind, placebo-controlled APOLLO trial.
Bitopertin is an investigational agent and is not approved for use as a therapy in any jurisdiction worldwide. Disc obtained global rights to bitopertin under a license agreement from Roche in May 2021.
About Disc Medicine
Disc Medicine (NASDAQ:IRON) is a clinical-stage biopharmaceutical company committed to discovering, developing, and commercializing novel treatments for patients who suffer from serious hematologic diseases. We are building a portfolio of innovative, potentially first-in-class therapeutic candidates that aim to address a wide spectrum of hematologic diseases by targeting fundamental biological pathways of red blood cell biology, specifically heme biosynthesis and iron homeostasis. For more information, please visit
www.discmedicine.com
.
Media Contact
Peg Rusconi
Deerfield Group
peg.rusconi@deerfieldgroup.com
Investor Relations Contact
Kevin Lui
Precision AQ
kevin.lui@precisionaq.com
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
9cf68d1db9· 2026-10-19 05:02 · doubao / doubao-seed-evolving-latest-version · 策略包658c0c1e2ba5当前